$SVRA News

Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment

Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP Patients

Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside

JP Morgan Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $12

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress

Savara Announces New Employment Inducement Grant

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041

Savara Q2 EPS $(0.16) Misses $(0.14) Estimate

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

Savara Announces New Employment Inducement Grant

Savara Announces Chief Financial and Administrative Officer Transition

Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns

Savara Chief Financial And Administrative Officer Dave Lowrance Stepping Down, Effective July 15; COO Robert Lutz To Assume Additional Role Of CFO

Savara: The Rare Disease Funnel Is Becoming A Commercial Asset